Development

Feliza Mirasol is the science editor for 

Articles

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk

Preclinical testing is better able to evaluate complex drug candidates thanks to innovations in animal model approaches.

Animal Models Are Seeing Upgrades to Tackle Complex Molecule Testing

Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.

Precision BioSciences Releases Data on CAR T Therapy Candidates

Peter Gaskin, PhD, is the senior director of scientific advisory services for Charles River, an AAPS sustaining partner.

To build trust and ensure a high-quality product, companies must be sure their contracts are firm and their lines of communication even firmer.

The Essential Ingredient in any Sponsor-CRO Partnership: Trust

Meg Rivers is the former senior editor for 

New technologies are treatments are emerging to tackle COVID-19 and its assortment of new variants.

The Next Step For COVID-19 Vaccines

Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants. 

What’s Next for COVID-19 Vaccines and Variants? 

Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.

Sanofi to Acquire Origimm Biotechnology for Vaccine-based Acne Treatment

Secarna Pharmaceuticals and Achilles Therapeutics have entered into an agreement to optimize the development of T cell therapies in Achilles’ pipeline.

Secarna Pharmaceuticals and Achilles Therapeutics Partner on T Cell Therapy Development

The biopharma industry is seeing more merit in strategizing clinical and commercial drug development as early as the preclinical phase.

Biopharma Industry is Seeing Merit in Early Preclinical Strategies

MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, signed an agreement with Cellecta to license its genome-editing tool.




Early Phase Development